MoonLake Immunotherapeutics
NASDAQ:MLTXBiotechnology
Healthcare
$10.79 +0.69%
+$0.13 today
- Market cap
- $918.30M
- Beta
- 1.04
- P/E (TTM)
- -5.4
- EPS (TTM)
- -$3.61
52W Low $5.95High $62.75
Volume 1.32M
Average 0.99M
MLTX EBITDA Margin
EBITDA as a percentage of revenue.
No reported EBITDA Margin figures are available to summarize.
EBITDA Margin history
Percent of revenue · from the income statement
No EBITDA Margin data reported for this period type.
EBITDA Margin vs competitors
How MLTX compares with its peers on the latest reported figures
MLTX Competitors Peer median
| Company | Period | LTM level | YoY | 3-year change |
|---|---|---|---|---|
| LTM Aug 2026 | 46.0% | +315.4 pp | +147.4 pp | |
| LTM Mar 2026 | 25.2% | +93.4 pp | +1052.7 pp | |
| LTM Mar 2026 | -843.9% | -542.0 pp | -540.2 pp | |
| LTM Jun 2026 | -1550.9% | +804.4 pp | -7510.8 pp | |
| FY2025 | -4915.2% | — | — | |
ALMSAlumis Inc. Common Stock | LTM Jun 2026 | -5986.3% | -3970.2 pp | — |
| FY2025 | -85279.7% | -85223.0 pp | — | |
| FY2025 | — | — | — | |
ORKAOruka Therapeutics, Inc. | FY2025 | — | — | — |
ZURAZura Bio Limited | FY2025 | — | — | — |
| FY2025 | — | — | — | |
| Peer median (excluding MLTX) | -1550.9% | -224.3 pp | -196.4 pp | |
Competitors are the stored peer set for MLTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
USD
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 4.97K | 0 | 0 | 0 | 2.62M |
| Gross Profit | (4.97K) | 0 | 0 | 0 | (2.62M) |
| Gross Margin | — | — | — | — | — |
| Research & Development | 35.52M | 42.05M | 31.8M | 112.77M | 202.86M |
| Selling, General & Admin | 18.05M | 23.01M | 22.32M | 30.32M | 41.97M |
| Operating Expenses | 53.57M | 65.06M | 54.12M | 143.09M | 242.22M |
| Depreciation & Amortization | 4.97K | 164.78K | 370.32K | 1.38M | 2.62M |
| EBITDA | (53.63M) | (64.3M) | (43.61M) | (119.58M) | (219.85M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (53.58M) | (65.06M) | (54.12M) | (143.09M) | (244.83M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 0 | 0 | 0 | 0 | 0 |
| Interest Expense | 0 | 0 | 0 | 0 | 7.25M |
| Other Income / Expenses | (61.85K) | 591.73K | 10.14M | 22.13M | 15.12M |
| Income Before Tax | (53.64M) | (64.47M) | (43.98M) | (120.96M) | (229.71M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 4.76K | 36.37K | 94.39K | 282.2K | 611K |
| Net Income | (53.64M) | (49.97M) | (36.01M) | (118.94M) | (227.32M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (1.45) | (2.20) | (0.73) | (1.89) | (3.53) |
| EPS (Diluted) | (1.45) | (2.20) | (0.73) | (1.89) | (3.53) |
| Weighted Avg Shares | 36.93M | 29.36M | 49.12M | 62.87M | 64.46M |
| Weighted Avg Shares (Diluted) | 36.93M | 29.36M | 49.12M | 62.87M | 64.46M |
MoonLake Immunotherapeutics
NASDAQ:MLTX
Intrinsic Alpha fair value
Locked
Current Price
$10.79
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.